|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0019682,
umls-concept:C0019699,
umls-concept:C0019704,
umls-concept:C0021311,
umls-concept:C0085432,
umls-concept:C0205390,
umls-concept:C0439662,
umls-concept:C0936012,
umls-concept:C1171370,
umls-concept:C1257890,
umls-concept:C1709737
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1998-3-6
|
|
pubmed:abstractText |
Among 2099 uninfected subjects in phase I and II trials of candidate AIDS vaccines, 23 were diagnosed with intercurrent human immunodeficiency virus type 1 (HIV-1) infection. High-risk sexual exposures accounted for 17 infections, and intravenous drug use accounted for 6. Four subjects received placebo, 13 received a complete immunization schedule (> or = 3 injections), and 6 were partially immunized (< or = 2 injections). There was no significant difference between vaccine recipients and control groups in incidence of HIV-1 infection, virus load, CD4 lymphocyte count, or V3 loop amino acid sequence. In summary, 19 vaccinated subjects acquired HIV-1 infection during phase I and II trials, indicating that immunization with the products described is < 100% effective in preventing or rapidly clearing infection. Laboratory analysis suggested that vaccine-induced immune responses did not significantly affect the genotypic or phenotypic characteristics of transmitted virus or the early clinical course of HIV-1 infection.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:BelsheR BRB,
pubmed-author:ConnorR IRI,
pubmed-author:CoreyLL,
pubmed-author:DolinRR,
pubmed-author:FastP EPE,
pubmed-author:GorseG JGJ,
pubmed-author:GrahamB SBS,
pubmed-author:KeeferM CMC,
pubmed-author:KorberB TBT,
pubmed-author:LambertJ SJS,
pubmed-author:MatthewsT JTJ,
pubmed-author:McElrathM JMJ,
pubmed-author:MontefioriD CDC,
pubmed-author:MulliganM JMJ,
pubmed-author:SchwartzD HDH,
pubmed-author:VermundS HSH,
pubmed-author:WolfeM JMJ,
pubmed-author:WolinskyS MSM,
pubmed-author:WrightP FPF
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
177
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
310-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9466516-AIDS Vaccines,
pubmed-meshheading:9466516-Adult,
pubmed-meshheading:9466516-Amino Acid Sequence,
pubmed-meshheading:9466516-CD4 Lymphocyte Count,
pubmed-meshheading:9466516-Female,
pubmed-meshheading:9466516-HIV Antibodies,
pubmed-meshheading:9466516-HIV Envelope Protein gp120,
pubmed-meshheading:9466516-HIV Infections,
pubmed-meshheading:9466516-HIV-1,
pubmed-meshheading:9466516-Humans,
pubmed-meshheading:9466516-Immunity, Active,
pubmed-meshheading:9466516-Incidence,
pubmed-meshheading:9466516-Male,
pubmed-meshheading:9466516-Middle Aged,
pubmed-meshheading:9466516-Molecular Sequence Data,
pubmed-meshheading:9466516-Neutralization Tests,
pubmed-meshheading:9466516-Peptide Fragments,
pubmed-meshheading:9466516-Risk-Taking,
pubmed-meshheading:9466516-Sequence Analysis,
pubmed-meshheading:9466516-Substance Abuse, Intravenous,
pubmed-meshheading:9466516-Viral Load
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.
|
|
pubmed:affiliation |
Vanderbilt University School of Medicine, Nashville, Tennessee 37232-2582, USA. barney.graham@mcmail.vanderbilt.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
